Bioxcel Therapeutics Stock News

BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (dexmedetomidine) sublingual film fo

Shares of BioXcel Therapeutics Inc. BTAI, -2.98% jumped 14.6% in premarket trading on Wednesday after the company said the Food and Drug Administration approved Igalmi, a sublingual film used to treat

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy P

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it

Investors may be anticipating a positive review by the FDA of the company's lead drug candidate.

Investors may be anticipating a positive review by the FDA of the company's lead drug candidate.

We are initiating coverage on BTAI with a target price of USD 126 (+600% potential upside) and a potential 60% downside (~$7 cash value). We like the risk-reward set-up for the company.

Shares of BioXcel Therapeutics (BTAI) are trading down even though the companys Q4 2021 earnings beat on the bottom line.

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2021 Results - Earnings Call Transcript

BioXcel Therapeutics press release (BTAI): Q4 GAAP EPS of -$0.93 beats by $0.21.As of December 31, 2021, cash and cash equivalents totaled approximately $233.0M.

Ready to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date

Ready to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date

NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tra

NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will present at the upcoming Barclays Global Healthcare Conference on Tuesday, March 15 at 3:50 p.m. ET. Dr. Mehta will highlight the Company’s neuroscience and immuno-oncology programs, artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process, and its commercial and launch readiness plans for its product candidate, BXCL501.